drugset / Trial / NCT00002855

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

NCT00002855

RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.

Timeline

Start
1996-08
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Ketoconazole Small molecule
Subject Nilutamide Small molecule
Subject Vinblastine Small molecule
Subject estramustine Other / unclassified
Subject flutamide Small molecule
Background Hydrocortisone Other / unclassified

Indications